Trial reportJAMA ophthalmology2013
Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
Trial report in JAMA ophthalmology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00996437 (An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy), which is not on this map. Cited by 53 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy
Who cites it
53 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- A systematic review and meta-analysis of the effect of intravitreal VEGF inhibitors on cardiorenal outcomes.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023Pooled it
- Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.The Cochrane database of systematic reviews · 2023Pooled it
- Anti-Vascular Endothelial Growth Factor Therapy as an Alternative or Adjunct to Pan-Retinal Photocoagulation in Treating Proliferative Diabetic Retinopathy: Meta-Analysis of Randomized Trials.Frontiers in pharmacology · 2020Pooled it
- Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.The Cochrane database of systematic reviews · 2014Pooled it
- Pooled it
- Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study.The British journal of ophthalmology · 2022Trial
- Trial
- Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial.BMC ophthalmology · 2020Trial
- Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.Ophthalmology · 2019Trial
- Trial
- Evaluation of results 1 year following short-term use of ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy.JAMA ophthalmology · 2014Trial
- Short-term treatment outcomes of the ranibizumab biosimilar CKD-701 for vitreous hemorrhage secondary to proliferative diabetic retinopathy.BMC ophthalmology · 2026Article
- Ultra-Widefield Fluorescein Angiographic Quantitative Leakage Parameters and Clinical Outcomes in Nonproliferative Diabetic Retinopathy.JAMA ophthalmology · 2026Observational
- Endocrinology concepts for diabetic retinopathy care: bridging systemic metabolic control with retinal disease management and patient education.Frontiers in medicine · 2026Review
- Posterior Vitreous Detachment Determines the Clinical Impact of Fibrovascular Membrane Fibrosis After Anti-VEGF Treatment in Proliferative Diabetic Retinopathy: A Real-World Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Personalized Management of Patients with Proliferative Diabetic Vitreoretinopathy.Life (Basel, Switzerland) · 2024Article
- A retrospective study of ophthalmologic presentation, management, and outcomes in pediatric patients admitted with abusive head trauma.Frontiers in medicine · 2024Article
- Perspectives of diabetic retinopathy-challenges and opportunities.Eye (London, England) · 2023Review
- Vitreous hemorrhage - Causes, diagnosis, and management.Indian journal of ophthalmology · 2023Review
- VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy.Annals of medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
importanceVascular endothelial growth factor plays a role in proliferative diabetic retinopathy (PDR). Intravitreal injection of saline has been shown potentially to lead to improved visual acuity compared with observation alone in eyes with vitreous hemorrhage. Therefore, it is important to determine if intravitreal anti-vascular endothelial growth factor can reduce vitrectomy rates (and risks associated with vitrectomy) compared with saline for vitreous hemorrhage from PDR that precludes placement or confirmation of complete panretinal photocoagulation.
objectiveTo evaluate intravitreal ranibizumab compared with intravitreal saline injections on vitrectomy rates for vitreous hemorrhage from PDR.
designPhase 3, double-masked, randomized, multicenter clinical trial. Data reported were collected from June 2010 to March 2012 and include 16 weeks of follow-up.
settingCommunity-based and academic-based ophthalmology practices specializing in retinal diseases.
participantsTwo hundred sixty-one eyes of 261 study participants, who were at least 18 years of age with type 1 or type 2 diabetes mellitus. Study eyes had vitreous hemorrhage from PDR precluding panretinal photocoagulation completion.
interventionEyes were randomly assigned to 0.5-mg intravitreal ranibizumab (n = 125) or intravitreal saline (n = 136) at baseline and 4 and 8 weeks.
main outcome measureCumulative probability of vitrectomy within 16 weeks.
resultsCumulative probability of vitrectomy by 16 weeks was 12% with ranibizumab vs 17% with saline (difference, 4%; 95% CI, -4% to 13%) and of complete panretinal photocoagulation without vitrectomy by 16 weeks was 44% and 31%, respectively (P = .05). The mean (SD) visual acuity improvement from baseline to 12 weeks was 22 (23) letters and 16 (31) letters, respectively (P = .04). Recurrent vitreous hemorrhage occurred within 16 weeks in 6% and 17%, respectively (P = .01). One eye developed endophthalmitis after saline injection. CONCLUSIONS AND RELEVANCE: Overall, the 16-week vitrectomy rates were lower than expected in both groups. This study suggests little likelihood of a clinically important difference between ranibizumab and saline on the rate of vitrectomy by 16 weeks in eyes with vitreous hemorrhage from PDR. Short-term secondary outcomes including visual acuity improvement, increased panretinal photocoagulation completion rates, and reduced recurrent vitreous hemorrhage rates suggest biologic activity of ranibizumab. Long-term benefits remain unknown. Whether vitrectomy rates after saline or ranibizumab injection are different than observation alone cannot be determined from this study.
trial registrationThe study is listed on www.clinicaltrials.gov, under identifier NCT00996437 (website registration date October 14, 2009).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.